Insmed Inc Stock Performance
| INSM Stock | USD 79.05 0.95 1.22% |
Insmed has a performance score of 4 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.48, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Insmed's returns are expected to increase less than the market. However, during the bear market, the loss of holding Insmed is expected to be smaller as well. Insmed Inc right now retains a risk of 2.26%. Please check out Insmed value at risk, as well as the relationship between the skewness and day median price , to decide if Insmed will be following its current trending patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Insmed Inc are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Insmed may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
Actual Historical Performance (%)
One Day Return 0.77 | Five Day Return (7.53) | Year To Date Return 11.65 | Ten Year Return 321.25 | All Time Return (52.67) |
Last Split Factor 1:10 | Last Split Date 2011-03-03 |
1 | Disposition of 32156 shares by Bonstein Sara of Insmed at 17.07 subject to Rule 16b-3 | 12/03/2024 |
2 | Disposition of 18750 shares by Lewis William of Insmed at 22.76 subject to Rule 16b-3 | 12/12/2024 |
3 | Heres How Much You Would Have Made Owning Insmed Stock In The Last 10 Years | 01/02/2025 |
4 | Disposition of 11504 shares by Lewis William of Insmed at 72.58 subject to Rule 16b-3 | 01/03/2025 |
5 | Disposition of 2444 shares by Roger Adsett of Insmed at 65.95 subject to Rule 16b-3 | 01/07/2025 |
6 | Disposition of 872 shares by Schaeffer Orlov S Nicole of Insmed at 68.72 subject to Rule 16b-3 | 01/14/2025 |
7 | Insider Sell Schaeffer Orlov S Nicole Sells Shares of Insmed Inc | 01/17/2025 |
8 | Disposition of 50000 shares by Schaeffer Orlov S Nicole of Insmed at 16.16 subject to Rule 16b-3 | 01/30/2025 |
9 | Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635 | 02/07/2025 |
10 | Insmed Expected to Beat Earnings Estimates What to Know Ahead of Q4 Release | 02/13/2025 |
11 | Palo Alto Investors LP Reduces Stake in Revance Therapeutics Inc | 02/14/2025 |
12 | Disposition of 700 shares by Bonstein Sara of Insmed at 81.0 subject to Rule 16b-3 | 02/18/2025 |
13 | Insmed Reports Q4 Earnings What Key Metrics Have to Say | 02/20/2025 |
14 | Truist Financial Issues Positive Forecast for Insmed Stock Price | 02/21/2025 |
15 | Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiect... | 02/24/2025 |
16 | Buy this biopharmaceutical stock that can rally 25, says RBC Capital Markets | 02/25/2025 |
| Begin Period Cash Flow | 482.4 M |
Insmed |
Insmed Relative Risk vs. Return Landscape
If you would invest 7,516 in Insmed Inc on November 29, 2024 and sell it today you would earn a total of 523.00 from holding Insmed Inc or generate 6.96% return on investment over 90 days. Insmed Inc is currently generating 0.1371% in daily expected returns and assumes 2.2564% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Insmed, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Insmed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Insmed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Insmed Inc, and traders can use it to determine the average amount a Insmed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0608
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | INSM | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.26 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Insmed is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Insmed by adding it to a well-diversified portfolio.
Insmed Fundamentals Growth
Insmed Stock prices reflect investors' perceptions of the future prospects and financial health of Insmed, and Insmed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Insmed Stock performance.
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (2.51) % | ||||
| Operating Margin | (2.35) % | ||||
| Current Valuation | 13.74 B | ||||
| Shares Outstanding | 181 M | ||||
| Price To Earning | (8.70) X | ||||
| Price To Book | 49.15 X | ||||
| Price To Sales | 38.87 X | ||||
| Revenue | 363.71 M | ||||
| Gross Profit | 277.96 M | ||||
| EBITDA | (818.79 M) | ||||
| Net Income | (913.77 M) | ||||
| Cash And Equivalents | 554.87 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 45.49 M | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 1.59 X | ||||
| Cash Flow From Operations | (683.88 M) | ||||
| Earnings Per Share | (5.62) X | ||||
| Market Capitalization | 14.14 B | ||||
| Total Asset | 2.03 B | ||||
| Retained Earnings | (4.36 B) | ||||
| Working Capital | 1.32 B | ||||
| Current Asset | 28.15 M | ||||
| Current Liabilities | 3.89 M | ||||
About Insmed Performance
By examining Insmed's fundamental ratios, stakeholders can obtain critical insights into Insmed's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Insmed is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 419.64 | 547.40 | |
| Return On Tangible Assets | (0.50) | (0.52) | |
| Return On Capital Employed | (0.51) | (0.48) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (3.20) | (3.04) |
Things to note about Insmed Inc performance evaluation
Checking the ongoing alerts about Insmed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Insmed Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 363.71 M. Net Loss for the year was (913.77 M) with profit before overhead, payroll, taxes, and interest of 277.96 M. | |
| Insmed Inc currently holds about 554.87 M in cash with (683.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
| Insmed Inc has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from cnbc.com: Buy this biopharmaceutical stock that can rally 25, says RBC Capital Markets |
- Analyzing Insmed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Insmed's stock is overvalued or undervalued compared to its peers.
- Examining Insmed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Insmed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Insmed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Insmed's stock. These opinions can provide insight into Insmed's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.62) | Revenue Per Share | Quarterly Revenue Growth 0.248 | Return On Assets | Return On Equity |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.